|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"muro k"
Showing items 1-38 of 38 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 臺大學術典藏 |
2022-09-15T01:08:49Z |
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia
|
Chia-Chi Lin; Doi T.; Muro K.; Hou M.-M.; Esaki T.; Hara H.; Chung H.C.; Helwig C.; Dussault I.; Osada M.; Kondo S. |
| 臺大學術典藏 |
2022-01-05T03:36:40Z |
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study
|
Kang Y.-K.; Morita S.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Sameshima H.; Chen L.-T.; Boku N. |
| 臺大學術典藏 |
2022-01-05T03:36:39Z |
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
|
Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Nishiyama T.; Chen L.-T.; Kang Y.-K. |
| 國家衛生研究院 |
2021-09-04 |
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: Post hoc subanalysis from the ATTRACTION-2 study
|
Kang, YK;Morita, S;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Sameshima, H;Chen, LT;Boku, N |
| 國家衛生研究院 |
2021-03-20 |
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
|
Boku, N;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Nishiyama, T;Chen, LT;Kang, YK |
| 臺大學術典藏 |
2021-02-19T06:52:26Z |
Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer
|
Kojima T.;Shah M.A.;Muro K.;Francois E.;Adenis A.;Chih-Hung Hsu;Doi T.;Moriwaki T.;Kim S.-B.;Lee S.-H.;Bennouna J.;Kato K.;Shen L.;Enzinger P.;Qin S.-K.;Ferreira P.;Chen J.;Girotto G.;De La Fouchardiere C.;Senellart H.;Al-Rajabi R.;Lordick F.;Wang R.;Suryawanshi S.;Bhagia P.;Peter Kang S.;Metges J.-P.;Keynote-181 Investigators; Kojima T.; Shah M.A.; Muro K.; Francois E.; Adenis A.; CHIH-HUNG HSU; Doi T.; Moriwaki T.; Kim S.-B.; Lee S.-H.; Bennouna J.; Kato K.; Shen L.; Enzinger P.; Qin S.-K.; Ferreira P.; Chen J.; Girotto G.; de la Fouchardiere C.; Senellart H.; Al-Rajabi R.; Lordick F.; Wang R.; Suryawanshi S.; Bhagia P.; Peter Kang S.; Metges J.-P.; KEYNOTE-181 Investigators |
| 臺大學術典藏 |
2021-01-28T01:06:36Z |
Everolimus for previously treated advanced gastric cancer: Results of the randomized, double-blind, phase III GRANITE-1 study
|
Ohtsu A.;Ajani J.A.;Bai Y.-X.;Bang Y.-J.;Chung H.-C.;Pan H.-M.;Sahmoud T.;Shen L.;Kun-Huei Yeh;Chin K.;Muro K.;Kim Y.H.;Ferry D.;Tebbutt N.C.;Al-Batran S.-E.;Smith H.;Costantini C.;Rizvi S.;Lebwohl D.;Van Cutsem E.; Ohtsu A.; Ajani J.A.; Bai Y.-X.; Bang Y.-J.; Chung H.-C.; Pan H.-M.; Sahmoud T.; Shen L.; KUN-HUEI YEH; Chin K.; Muro K.; Kim Y.H.; Ferry D.; Tebbutt N.C.; Al-Batran S.-E.; Smith H.; Costantini C.; Rizvi S.; Lebwohl D.; Van Cutsem E. |
| 臺大學術典藏 |
2021-01-28T01:06:21Z |
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: A JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
|
Yoshino T.;Arnold D.;Taniguchi H.;Pentheroudakis G.;Yamazaki K.;Xu R.-H.;Kim T.W.;Ismail F.;Tan I.B.;Kun-Huei Yeh;Grothey A.;Zhang S.;Ahn J.B.;Mastura M.Y.;Chong D.;Chen L.-T.;Kopetz S.;Eguchi-Nakajima T.;Ebi H.;Ohtsu A.;Cervantes A.;Muro K.;Tabernero J.;Minami H.;Ciardiello F.;Douillard J.-Y.; Yoshino T.; Arnold D.; Taniguchi H.; Pentheroudakis G.; Yamazaki K.; Xu R.-H.; Kim T.W.; Ismail F.; Tan I.B.; KUN-HUEI YEH; Grothey A.; Zhang S.; Ahn J.B.; Mastura M.Y.; Chong D.; Chen L.-T.; Kopetz S.; Eguchi-Nakajima T.; Ebi H.; Ohtsu A.; Cervantes A.; Muro K.; Tabernero J.; Minami H.; Ciardiello F.; Douillard J.-Y. |
| 臺大學術典藏 |
2021-01-28T01:06:21Z |
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Kang Y.-K.;Boku N.;Satoh T.;Ryu M.-H.;Chao Y.;Kato K.;Chung H.C.;Chen J.-S.;Muro K.;Kang W.K.;Kun-Huei Yeh;Yoshikawa T.;Oh S.C.;Bai L.-Y.;Tamura T.;Lee K.-W.;Hamamoto Y.;Kim J.G.;Chin K.;Oh D.-Y.;Minashi K.;Cho J.Y.;Tsuda M.;Chen L.-T.; Kang Y.-K.; Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Chen L.-T. |
| 臺大學術典藏 |
2021-01-28T01:06:20Z |
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYnote-061): a randomised, open-label, controlled, phase 3 trial
|
Shitara K.;?Zg?Ro?Lu M.;Bang Y.-J.;Di Bartolomeo M.;Mandal? M.;Ryu M.-H.;Fornaro L.;Olesi?Ski T.;Caglevic C.;Chung H.C.;Muro K.;Goekkurt E.;Mansoor W.;Mcdermott R.S.;Shacham-Shmueli E.;Chen X.;Mayo C.;Kang S.P.;Ohtsu A.;Fuchs C.S.;Lerzo G.;O'Connor J.M.;Mendez G.A.;Lynam J.;Tebbutt N.;Wong M.;Strickland A.;Karapetis C.;Goldstein D.;Vasey P.;Van Laethem J.-L.;Van Cutsem E.;Berry S.;Vincent M.;Muller B.;Rey F.;Zambrano A.;Guerra J.;Krogh M.;Baeksgaard L.;Yilmaz M.;Elme A.;Magi A.;Auvinen P.;Alanko T.;Moehler M.;Kunzmann V.;Seufferlein T.;Thuss-Patience P.;Goekkurt E.;Hoehler T.;Haag G.;Al-Batran S.-E.;Castro H.;Lopez K.;Aguilar Vasquez M.;Sandoval M.;Lam K.O.;Cuffe S.;Kelly C.;Geva R.;Shacham-Shmueli E.;Hubert A.;Beny A.;Brenner B.;Giuseppe A.;Falcone A.;Maiello E.;Passalacqua R.;Montesarchio V.;Hara H.;Chin K.;Nishina T.;Komatsu Y.;Machida N.;Hironaka S.;Satoh T.;Tamura T.;Sugimoto N.;Cho H.;Omuro Y.;Kato K.;Goto M.;Hyodo I.;Yoshida K.;Baba H.;Esaki T.;Furuse J.;Wan Mohammed W.Z.;Hernandez Hernandez C.;Casas Garcia J.;Dominguez Andrade A.;Clarke K.;Hjortland G.;Glenjen N.;Kubiatowski T.;Jacek J.;Wojtukiewicz M.;Lazarev S.;Lancukhay Y.;Afanasayev S.;Moiseyenko V.;Kostorov V.;Protsenko S.;Shirinkin V.;Sakaeva D.;Fadeeva N.;Yong W.P.;Ng C.H.M.;Robertson B.;Rapaport B.;Cohen G.;Dreosti L.;Ruff P.;Jacobs C.;Landers G.;Szpak W.;Roh S.-Y.;Lee J.;Kim Y.H.;Bang Y.-J.;Chung H.C.;Ryu M.-H.;Alsina Maqueda M.;Longo Munoz F.;Cervantes Aguilar A.;Aranda Aguilar E.;Garcia Alfonso P.;Rivera F.;Feliu Batle J.;Pazo Cid R.;Kun-Huei Yeh;Chen J.-S.;Chao Y.;Yen C.-J.;?Zg?Ro?Lu M.;Kara O.;Yalcin S.;Hochhauser D.;Chau I.;Benson A.;Shankaran V.;Shaib W.;Philip P.;Sharma V.;Siegel R.;Sun W.;Wainberg Z.;George B.;Bullock A.;Myrick S.;Faruol J.;Siegel R.;Larson T.;Becerra C.;Ratnam S.;Richards D.A.;Riche S.L.;Keynote-061 Investigators; Shitara K.; ?zg?ro?lu M.; Bang Y.-J.; Di Bartolomeo M.; Mandal? M.; Ryu M.-H.; Fornaro L.; Olesi?ski T.; Caglevic C.; Chung H.C.; Muro K.; Goekkurt E.; Mansoor W.; McDermott R.S.; Shacham-Shmueli E.; Chen X.; Mayo C.; Kang S.P.; Ohtsu A.; Fuchs C.S.; Lerzo G.; O'Connor J.M.; Mendez G.A.; Lynam J.; Tebbutt N.; Wong M.; Strickland A.; Karapetis C.; Goldstein D.; Vasey P.; Van Laethem J.-L.; Van Cutsem E.; Berry S.; Vincent M.; Muller B.; Rey F.; Zambrano A.; Guerra J.; Krogh M.; Baeksgaard L.; Yilmaz M.; Elme A.; Magi A.; Auvinen P.; Alanko T.; Moehler M.; Kunzmann V.; Seufferlein T.; Thuss-Patience P.; Goekkurt E.; Hoehler T.; Haag G.; Al-Batran S.-E.; Castro H.; Lopez K.; Aguilar Vasquez M.; Sandoval M.; Lam K.O.; Cuffe S.; Kelly C.; Geva R.; Shacham-Shmueli E.; Hubert A.; Beny A.; Brenner B.; Giuseppe A.; Falcone A.; Maiello E.; Passalacqua R.; Montesarchio V.; Hara H.; Chin K.; Nishina T.; Komatsu Y.; Machida N.; Hironaka S.; Satoh T.; Tamura T.; Sugimoto N.; Cho H.; Omuro Y.; Kato K.; Goto M.; Hyodo I.; Yoshida K.; Baba H.; Esaki T.; Furuse J.; Wan Mohammed W.Z.; Hernandez Hernandez C.; Casas Garcia J.; Dominguez Andrade A.; Clarke K.; Hjortland G.; Glenjen N.; Kubiatowski T.; Jacek J.; Wojtukiewicz M.; Lazarev S.; Lancukhay Y.; Afanasayev S.; Moiseyenko V.; Kostorov V.; Protsenko S.; Shirinkin V.; Sakaeva D.; Fadeeva N.; Yong W.P.; Ng C.H.M.; Robertson B.; Rapaport B.; Cohen G.; Dreosti L.; Ruff P.; Jacobs C.; Landers G.; Szpak W.; Roh S.-Y.; Lee J.; Kim Y.H.; Bang Y.-J.; Chung H.C.; Ryu M.-H.; Alsina Maqueda M.; Longo Munoz F.; Cervantes Aguilar A.; Aranda Aguilar E.; Garcia Alfonso P.; Rivera F.; Feliu Batle J.; Pazo Cid R.; KUN-HUEI YEH; Chen J.-S.; Chao Y.; Yen C.-J.; ?zg?ro?lu M.; Kara O.; Yalcin S.; Hochhauser D.; Chau I.; Benson A.; Shankaran V.; Shaib W.; Philip P.; Sharma V.; Siegel R.; Sun W.; Wainberg Z.; George B.; Bullock A.; Myrick S.; Faruol J.; Siegel R.; Larson T.; Becerra C.; Ratnam S.; Richards D.A.; Riche S.L.; KEYnote-061 investigators |
| 臺大學術典藏 |
2021-01-28T01:06:19Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
|
Muro K.;Van Cutsem E.;Narita Y.;Pentheroudakis G.;Baba E.;Li J.;Ryu M.-H.;Wan Zamaniah W.I.;Yong W.-P.;Kun-Huei Yeh;Kato K.;Lu Z.;Cho B.C.;Nor I.M.;Ng M.;Chen L.-T.;Nakajima T.E.;Shitara K.;Kawakami H.;Tsushima T.;Yoshino T.;Lordick F.;Martinelli E.;Smyth E.C.;Arnold D.;Minami H.;Tabernero J.;Douillard J.-Y.; Muro K.; Van Cutsem E.; Narita Y.; Pentheroudakis G.; Baba E.; Li J.; Ryu M.-H.; Wan Zamaniah W.I.; Yong W.-P.; KUN-HUEI YEH; Kato K.; Lu Z.; Cho B.C.; Nor I.M.; Ng M.; Chen L.-T.; Nakajima T.E.; Shitara K.; Kawakami H.; Tsushima T.; Yoshino T.; Lordick F.; Martinelli E.; Smyth E.C.; Arnold D.; Minami H.; Tabernero J.; Douillard J.-Y. |
| 臺大學術典藏 |
2021-01-28T01:06:18Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
|
Muro K.;Lordick F.;Tsushima T.;Pentheroudakis G.;Baba E.;Lu Z.;Cho B.C.;Nor I.M.;Ng M.;Chen L.-T.;Kato K.;Li J.;Ryu M.-H.;Wan Zamaniah W.I.;Yong W.-P.;Kun-Huei Yeh;Nakajima T.E.;Shitara K.;Kawakami H.;Narita Y.;Yoshino T.;Van Cutsem E.;Martinelli E.;Smyth E.C.;Arnold D.;Minami H.;Tabernero J.;Douillard J.-Y.; Muro K.; Lordick F.; Tsushima T.; Pentheroudakis G.; Baba E.; Lu Z.; Cho B.C.; Nor I.M.; Ng M.; Chen L.-T.; Kato K.; Li J.; Ryu M.-H.; Wan Zamaniah W.I.; Yong W.-P.; KUN-HUEI YEH; Nakajima T.E.; Shitara K.; Kawakami H.; Narita Y.; Yoshino T.; Van Cutsem E.; Martinelli E.; Smyth E.C.; Arnold D.; Minami H.; Tabernero J.; Douillard J.-Y. |
| 臺大學術典藏 |
2021-01-28T01:06:17Z |
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
|
Satoh T.; Kang Y.-K.; Chao Y.; Ryu M.-H.; Kato K.; Cheol Chung H.; Chen J.-S.; Muro K.; Ki Kang W.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Tanimoto M.; Chen L.-T.; Boku N. |
| 臺大學術典藏 |
2021-01-28T01:06:16Z |
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
|
Chen L.-T.;Satoh T.;Ryu M.-H.;Chao Y.;Kato K.;Chung H.C.;Chen J.-S.;Muro K.;Kang W.K.;Kun-Huei Yeh;Yoshikawa T.;Oh S.C.;Bai L.-Y.;Tamura T.;Lee K.-W.;Hamamoto Y.;Kim J.G.;Chin K.;Oh D.-Y.;Minashi K.;Cho J.Y.;Tsuda M.;Sameshima H.;Kang Y.-K.;Boku N.; Chen L.-T.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Sameshima H.; Kang Y.-K.; Boku N. |
| 國立成功大學 |
2021 |
Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials
|
Chao, J.;Fuchs, C.S.;Shitara, K.;Tabernero, J.;Muro, K.;Van, Cutsem E.;Bang, Y.-J.;De, Vita F.;Landers, G.;Yen, C.-J.;Chau, I.;Elme, A.;Lee, J.;Özgüroǧlu, M.;Catenacci, D.;Yoon, H.H.;Chen, E.;Adelberg, D.;Shih, C.-S.;Shah, Shah S.;Bhagia, P.;Wainberg, Z.A. |
| 國立成功大學 |
2021 |
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
|
Boku, N.;Satoh, T.;Ryu, M.-H.;Chao, Y.;Kato, Kato K.;Chung, H.C.;Chen, J.-S.;Muro, K.;Kang, W.K.;Yeh, K.-H.;Yoshikawa, T.;Oh, S.C.;Bai, L.-Y.;Tamura, Tamura T.;Lee, K.-W.;Hamamoto, Y.;Kim, J.G.;Chin, K.;Oh, D.-Y.;Minashi, K.;Cho, J.Y.;Tsuda, M.;Nishiyama, T.;Chen, L.-T.;Kang, Y.-K. |
| 臺大學術典藏 |
2020-08-13T06:33:32Z |
Ramucirumab safety in East Asian patients: A meta-analysis of six global, randomized, double-blind, placebo-controlled, phase III clinical trials
|
Zhang Y.; Sohn J.; Cheng R.; Yamazaki K.; Kim S.-W.; Chao Y.; Lee K.-W.; JIN-YUAN SHIH; Kudo M.; Kim T.-W.; Muro K.; Yen C.-J.; Yen C.-J.;Muro K.;Kim T.-W.;Kudo M.;Jin-Yuan Shih;Lee K.-W.;Chao Y.;Kim S.-W.;Yamazaki K.;Sohn J.;Cheng R.;Zhang Y.;Binder P.;Mi G.;Orlando M.;Chung H.C.; Binder P.; Mi G.; Orlando M.; Chung H.C. |
| 臺大學術典藏 |
2020-05-25T07:35:18Z |
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
|
McRee A.J; Chia-Chi Lin; Pathiraja K; Lunceford J; Emancipator K; Juco J; Koshiji M; Bang Y.-J.; Bang Y.-J.;Koshiji M;Juco J;Emancipator K;Lunceford J;Pathiraja K;Chia-Chi Lin;McRee A.J;Burtness B;Le D.T;Golan T;Eder J.P;Gupta S;Catenacci D;Geva R;Shankaran V;Chung H.C;Muro K; Muro K; Chung H.C; Shankaran V; Geva R; Catenacci D; Gupta S; Eder J.P; Golan T; Le D.T; Burtness B |
| 臺大學術典藏 |
2020-05-25T07:35:17Z |
Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results from the phase Ib KEYNOTE-012 expansion cohort
|
Seiwert T.Y.; Cheng J.D; Pathiraja K; Dolled-Filhart M; Meister A; Chung H.C; Chow L.Q.M; Haddad R; Gupta S; Mahipal A; Mehra R; Tahara M; Berger R; Eder J.P; Burtness B; Lee S.-H; Keam B; Kang H; Muro K; Weiss J; Geva R; Chia-Chi Lin |
| 臺大學術典藏 |
2020-05-25T07:35:12Z |
Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012
|
Tahara M; Muro K; Hasegawa Y; Chung H.C; Chia-Chi Lin; Keam B; Takahashi K; Cheng J.D; Bang Y.-J. |
| 臺大學術典藏 |
2020-05-25T07:35:10Z |
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: Pooled analyses after long-term follow-up in KEYNOTE-012
|
Cheng J; Chow L.Q.M; Haddad R.; Pathiraja K; Aurora-Garg D; Ray A; Chia-Chi Lin; Chung H.C; Geva R; Mehra R; Seiwert T.Y; Gupta S; Weiss J; Gluck I; Eder J.P; Burtness B; Tahara M; Keam B; Kang H; Muro K |
| 臺大學術典藏 |
2020-05-25T07:35:08Z |
Phase I study results from an esophageal squamous cell carcinoma (ESCC) cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor �] (TGF-�]) and PD-L1
|
Chia-Chi Lin; Doi T; Muro K; Hou M.-M; Esaki T; Hara H; Chung H.-C; Osada M; Helwig C; Kondo S. |
| 國家衛生研究院 |
2020-02 |
A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data
|
Chen, LT;Kang, YK;Satoh, T;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, W;Yoshikawa, T;Oh, SC;Tamura, T;Lee, KW;Boku, N |
| 國立成功大學 |
2020 |
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
|
Chen, L.-T.;Satoh, T.;Ryu, M.-H.;Chao, Y.;Kato, Kato K.;Chung, H.C.;Chen, J.-S.;Muro, K.;Kang, W.K.;Yeh, K.-H.;Yoshikawa, T.;Oh, S.C.;Bai, L.-Y.;Tamura, Tamura T.;Lee, K.-W.;Hamamoto, Y.;Kim, J.G.;Chin, K.;Oh, D.-Y.;Minashi, K.;Cho, J.Y.;Tsuda, M.;Sameshima, H.;Kang, Y.-K.;Boku, N. |
| 國立成功大學 |
2020 |
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
|
Satoh, T.;Kang, Y.-K.;Chao, Y.;Ryu, M.-H.;Kato, Kato K.;Cheol, Chung H.;Chen, J.-S.;Muro, K.;Ki, Kang W.;Yeh, K.-H.;Yoshikawa, T.;Oh, S.C.;Bai, L.-Y.;Tamura, Tamura T.;Lee, K.-W.;Hamamoto, Y.;Kim, J.G.;Chin, K.;Oh, D.-Y.;Minashi, K.;Cho, J.Y.;Tsuda, M.;Tanimoto, M.;Chen, L.-T.;Boku, N. |
| 國家衛生研究院 |
2019-12-20 |
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
|
Chen, LT;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Sameshima, H;Kang, YK;Boku, N |
| 國家衛生研究院 |
2019-05-13 |
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: A randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
|
Satoh, T;Kang, YK;Chao, Y;Ryu, MH;Kato, K;Cheol Chung, H;Chen, JS;Muro, K;Ki Kang, W;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Tanimoto, M;Chen, LT;Boku, N |
| 國家衛生研究院 |
2019-02 |
Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2
|
Kang, YK;Satoh, T;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yoshikawa, T;Oh, SC;Tamura, T;Lee, KW;Morita, S;Chen, LT;Boku, N |
| 國立成功大學 |
2019 |
Effect of First-line S-1 Plus Oxaliplatin with or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial
|
Yoshikawa, T.;Muro, K.;Shitara, K.;Oh, D.-Y.;Kang, Y.-K.;Chung, H.C.;Kudo, T.;Chin, K.;Kadowaki, S.;Hamamoto, Y.;Hironaka, S.;Yoshida, K.;Yen, C.-J.;Omuro, Y.;Bai, L.-Y.;Maeda, K.;Ozeki, A.;Yoshikawa, R.;Kitagawa, Y. |
| 國立成功大學 |
2019 |
A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy re
|
Kato, Kato K.;Satoh, T.;Muro, K.;Yoshikawa, T.;Tamura, Tamura T.;Hamamoto, Y.;Chin, K.;Minashi, K.;Tsuda, M.;Yamaguchi, K.;Machida, N.;Esaki, T.;Goto, M.;Komatsu, Y.;Nakajima, T.E.;Sugimoto, N.;Yoshida, K.;Oki, E.;Nishina, T.;Tsuji, A.;Fujii, H.;Kunieda, Kunieda K.;Saitoh, Saitoh S.;Omuro, Y.;Azuma, M.;Iwamoto, Y.;Taku, K.;Fushida, S.;Chen, L.-T.;Kang, Y.-K.;Boku, N. |
| 國家衛生研究院 |
2018-12-01 |
A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens
|
Kato, K;Satoh, T;Muro, K;Yoshikawa, T;Tamura, T;Hamamoto, Y;Chin, K;Minashi, K;Tsuda, M;Yamaguchi, K;Machida, N;Esaki, T;Goto, M;Komatsu, Y;Nakajima, TE;Sugimoto, N;Yoshida, K;Oki, E;Nishina, T;Tsuji, A;Fujii, H;Kunieda, K;Saitoh, S;Omuro, Y;Azuma, M;Iwamoto, Y;Taku, K;Fushida, S;Chen, LT;Kang, YK;Boku, N |
| 國家衛生研究院 |
2018-11-22 |
Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic gastric cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
|
Muro, K;Van Cutsem, E;Narita, Y;Pentheroudakis, G;Baba, E;Li, J;Ryu, MH;Zamaniah, WIW;Yong, WP;Yeh, KH;Kato, K;Lu, Z;Cho, BC;Nor, IM;Ng, M;Chen, LT;Nakajima, TE;Shitara, K;Kawakami, H;Tsushima, T;Yoshino, T;Lordick, F;Martinelli, E;Smyth, EC;Arnold, D;Minami, H;Tabernero, J;Douillard, JY |
| 國家衛生研究院 |
2018-11-22 |
Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic oesophageal cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
|
Muro, K;Lordick, F;Tsushima, T;Pentheroudakis, G;Baba, E;Lu, Z;Cho, BC;Nor, IM;Ng, M;Chen, LT;Kato, K;Li, J;Ryu, MH;Zamaniah, WIW;Yong, WP;Yeh, KH;Nakajima, TE;Shitara, K;Kawakami, H;Narita, Y;Yoshino, T;Van Cutsem, E;Martinelli, E;Smyth, EC;Arnold, D;Minami, H;Tabernero, J;Douillard, JY |
| 國立成功大學 |
2018 |
Ramucirumab safety in East Asian patients: A meta-analysis of six global, randomized, double-blind, placebo-controlled, phase III clinical trials
|
Yen, C.-J.;Muro, K.;Kim, T.-W.;Kudo, M.;Shih, J.-Y.;Lee, K.-W.;Chao, Y.;Kim, S.-W.;Yamazaki, K.;Sohn, J.;Cheng, R.;Zhang, Y.;Binder, P.;Mi, G.;Orlando, M.;Chung, H.C. |
| 國家衛生研究院 |
2017-12 |
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial
|
Kang, YK;Boku, N;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Chen, LT |
| 國家衛生研究院 |
2017-11-16 |
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer; A JSMO - ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
|
Yoshino, T;Arnold, D;Taniguchi, H;Pentheroudakis, G;Yamazaki, K;Xu, RH;Kim, TW;Ismail, F;Tan, IB;Yeh, KH;Grothey, A;Zhang, S;Ahn, JB;Chong, D;Chen, LT;Kopetz, S;Eguchi-Nakajima, T;Ebi, H;Ohtsu, A;Cervantes, A;Muro, K;Tabernero, J;Minami, H;Ciardiello, F;Douillard, JY |
| 國家衛生研究院 |
2017-09 |
A Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02)
|
Boku, N;Kang, YK;Satoh, T;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yoshikawa, T;Oh, SC;Tamura, T;Lee, KW;Chen, LT |
| 國家衛生研究院 |
2017-02 |
Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastroesophageal junction cancer (AGC): A double-blinded, randomized, phase III trial
|
Kang, YK;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yoshikawa, T;Oh, SC;Tamura, T;Lee, KW;Boku, N;Chen, LT |
Showing items 1-38 of 38 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
